Arbidol (ARB) is an antiviral compound that was originally proven effective for treatment of influenza and several other respiratory viral infections. The broad spectrum of ARB anti-viral activity led us to evaluate its effect on hepatitis C virus (HCV) infection and replication in cell culture. Long-term ARB treatment of Huh7 cells chronically replicating a genomic length genotype 1b replicon resulted in sustained reduction of viral RNA and protein expression, and eventually cured HCV infected cells. Pre-treatment of human hepatoma Huh7.5.1 cells with 15 μM ARB for 24 to 48 hours inhibited acute infection with JFH-1 virus by up to 1000-fold. The inhibitory effect of ARB on HCV was not due to generalized cytotoxicity, nor to augmentation of IFN antiviral signaling pathways, but involved impaired virus-mediated membrane fusion. ARB's affinity for membranes may inhibit several aspects of the HCV lifecycle that are membrane-dependent. © 2006 Boriskin et al; licensee BioMed Central Ltd.
CITATION STYLE
Boriskin, Y. S., Pécheur, E. I., & Polyak, S. J. (2006). Arbidol: A broad-spectrum antiviral that inhibits acute and chronic HCV infection. Virology Journal, 3. https://doi.org/10.1186/1743-422X-3-56
Mendeley helps you to discover research relevant for your work.